SCHEMBL5759527

SCHEMBL5759527

O=c1cc(C(F)(F)F)c2cc(Cc3ccc(S(=O)(=O)Nc4cccc5cccnc45)cc3)ccc2[nH]1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC40A1 Q9NP59 10/20 0.56
GLO1 Q04760 6/20 0.51
TDP1 Q9NUW8 6/20 0.48
KMT2A Q03164 5/20 0.48
MEN1 O00255 4/20 0.48
AGTR1 P30556 2/20 0.48
MITF O75030 1/20 0.48
S1PR4 O95977 1/20 0.48
ALDH1A1 P00352 1/20 0.48
LMNA P02545 1/20 0.48
MAPT P10636 1/20 0.48
S1PR1 P21453 1/20 0.48
OPRK1 P41145 1/20 0.48
HTT P42858 1/20 0.48
CKS1B P61024 1/20 0.48
SKP2 Q13309 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
NFKBIA P25963 2/20 0.48
G6PD P11413 1/20 0.48
METAP2 P50579 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5761661 0.89 CLK1 (0.52) SLC40A1GLO1TDP1KMT2AMEN1
SCHEMBL5860222 0.86 IDO1 (0.45) SLC40A1ALDH1A1MAPT
SCHEMBL5762713 0.84 ALDH1A1 (0.50) ALDH1A1LMNA
SCHEMBL5860398 0.83 SLC40A1 (0.55) SLC40A1GLO1TDP1KMT2AMEN1
SCHEMBL5761619 0.83 AR (0.42)
SCHEMBL5860121 0.83 MEN1 (0.45) KMT2AMEN1
SCHEMBL5860349 0.81 AR (0.42)
SCHEMBL5763565 0.80 SLC22A12 (0.52) KMT2AALDH1A1
SCHEMBL5761786 0.80 PKM (0.52) MAPT
SCHEMBL5860220 0.79 AR (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7098340-B2 Quinoline/chromene derivatives as androgen antagonist WARNER LAMBERT COMPANY LLC (US) 2006-08-29 US claimed
EP-1633732-A1 BENZYL SULFONAMIDE DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 2006-03-15 EP claimed
US-20050137228-A1 Benzyl sulfonamide derivatives DU DANIEL Y (US) 2005-06-23 US claimed
WO-2004101544-A1 BENZYL SULFONAMIDE DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY LLC (US) 2004-11-25 WO claimed
US-7098340-B2 Quinoline/chromene derivatives as androgen antagonist WARNER LAMBERT COMPANY LLC (US) 2006-08-29 US disclosed
US-20050137228-A1 Benzyl sulfonamide derivatives DU DANIEL Y (US) 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137228-A1 Benzyl sulfonamide derivatives AR, SHBG, BRDT SLC40A1 4682/4885GLO1 3516/4885TDP1 3413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.